Qiagen : Qiagen to discontinue NeuMoDx – adj. EPS FY24 guidance up by 2%
>Headwinds for PCR testing systems - Qiagen yesterday evening announced it is discontinuing the NeuMoDx integrated PCR testing system, given market development trends for these product lines following the Covid-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.NeuMoDx sales slumped by 60% since 2021 - During our GIS conference in January 2024, management already stated it would address the problems for...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.